School of Dentistry, University of California at Los Angeles, 10833 Le Conte Avenue, Los Angeles, CA 90095, USA.
Cancer Epidemiol Biomarkers Prev. 2012 Apr;21(4):664-72. doi: 10.1158/1055-9965.EPI-11-1093. Epub 2012 Feb 1.
Oral cancer is the sixth most common cancer with a 5-year survival rate of approximately 60%. Presently, there are no scientifically credible early detection techniques beyond conventional clinical oral examination. The goal of this study is to validate whether the seven mRNAs and three proteins previously reported as biomarkers are capable of discriminating patients with oral squamous cell carcinomas (OSCC) from healthy subjects in independent cohorts and by a National Cancer Institute (NCI)-Early Detection Research Network (EDRN)-Biomarker Reference Laboratory (BRL).
Three hundred and ninety-five subjects from five independent cohorts based on case controlled design were investigated by two independent laboratories, University of California, Los Angeles (Los Angeles, CA) discovery laboratory and NCI-EDRN-BRL.
Expression of all seven mRNA and three protein markers was increased in OSCC versus controls in all five cohorts. With respect to individual marker performance across the five cohorts, the increase in interleukin (IL)-8 and subcutaneous adipose tissue (SAT) was statistically significant and they remained top performers across different cohorts in terms of sensitivity and specificity. A previously identified multiple marker model showed an area under the receiver operating characteristic (ROC) curve for prediction of OSCC status ranging from 0.74 to 0.86 across the cohorts.
The validation of these biomarkers showed their feasibility in the discrimination of OSCCs from healthy controls. Established assay technologies are robust enough to perform independently. Individual cutoff values for each of these markers and for the combined predictive model need to be further defined in large clinical studies.
Salivary proteomic and transcriptomic biomarkers can discriminate oral cancer from control subjects.
口腔癌是第六大常见癌症，5 年生存率约为 60%。目前，除了常规临床口腔检查之外，尚无科学可信的早期检测技术。本研究的目的是验证之前报道的七种 mRNA 和三种蛋白质作为生物标志物是否能够在独立队列和国家癌症研究所（NCI）早期检测研究网络（EDRN）-生物标志物参考实验室（BRL）中区分口腔鳞状细胞癌（OSCC）患者与健康受试者。
基于病例对照设计的五个独立队列共 395 名受试者由两个独立实验室，加利福尼亚大学洛杉矶分校（洛杉矶，CA）发现实验室和 NCI-EDRN-BRL 进行研究。
所有五个队列的 OSCC 与对照相比，所有七种 mRNA 和三种蛋白质标志物的表达均增加。就五个队列中各个标志物的性能而言，白细胞介素（IL）-8 和皮下脂肪组织（SAT）的增加具有统计学意义，并且在不同队列中，它们在敏感性和特异性方面仍然是最佳标志物。之前确定的多个标志物模型显示，用于预测 OSCC 状态的接受者操作特征（ROC）曲线下面积（AUC）在队列之间的范围为 0.74 至 0.86。
这些生物标志物的验证表明它们在区分 OSCC 与健康对照方面具有可行性。既定的检测技术足够强大，可以独立运行。需要在大型临床研究中进一步确定这些标志物和联合预测模型的每个标志物的单独截断值。
唾液蛋白质组学和转录组学生物标志物可区分口腔癌与对照受试者。
